share_log

ProSomnus | POS AM: Post-effective amendment to a registration statement that is not immediately effective upon filing

SEC announcement ·  Feb 5 12:02
Summary by Moomoo AI
On February 2, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This filing is intended to convert the previously filed Registration Statement on Form S-1 into a registration statement on Form S-3. The original Registration Statement was declared effective by the SEC on December 14, 2023. The amendment does not register any additional securities and states that all applicable registration and filing fees were paid during the original filing. The prospectus included in the amendment details a secondary offering of up to 44,913,872 shares of common stock, which may be issued upon the exercise of warrants, the conversion of Series A Preferred Stock, as dividends on the Series A Preferred Stock, and upon conversion of convertible notes. ProSomnus, Inc. is a company specializing in the manufacture of precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea. The company's common stock is listed on the Nasdaq Global Market under the symbol 'OSA'.
On February 2, 2024, ProSomnus, Inc., a Delaware corporation, filed a post-effective amendment to its Form S-1 on Form S-3 with the Securities and Exchange Commission (SEC). This filing is intended to convert the previously filed Registration Statement on Form S-1 into a registration statement on Form S-3. The original Registration Statement was declared effective by the SEC on December 14, 2023. The amendment does not register any additional securities and states that all applicable registration and filing fees were paid during the original filing. The prospectus included in the amendment details a secondary offering of up to 44,913,872 shares of common stock, which may be issued upon the exercise of warrants, the conversion of Series A Preferred Stock, as dividends on the Series A Preferred Stock, and upon conversion of convertible notes. ProSomnus, Inc. is a company specializing in the manufacture of precision, mass-customized oral appliance therapy devices to treat obstructive sleep apnea. The company's common stock is listed on the Nasdaq Global Market under the symbol 'OSA'.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more